United States - English - NLM (National Library of Medicine)

biogen inc. - ranibizumab (unii: zl1r02vt79) (ranibizumab - unii:zl1r02vt79) - byooviz is indicated for the treatment of patients with: byooviz is contraindicated in patients with ocular or periocular infections. byooviz is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in byooviz. hypersensitivity reactions may manifest as severe intraocular inflammation. risk summary there are no adequate and well-controlled studies of ranibizumab products administered in pregnant women. administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure (based on maximal serum trough levels [cmax ]) after a single eye treatment at the recommended clinical dose. no skeletal abnormalities were observed at serum trough levels equivalent to the predicted human exposure after a single eye treatment at the recommended clinical dose [see animal data ]. animal reproduction studies are not always predictive of human re

European Union - English - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - lucentis is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to choroidal neovascularisation (cnv)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - ranibizumab - injection, solution - 3mg - ranibizumab 2.3mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride polysorbate 20 trehalose dihydrate water for injection - lucentis® is indicated for the treatment of neovascular (wet) age-related macular degeneration (amd).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - ranibizumab - solution for injection - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - ranibizumab - solution for injection - 10mg/1ml

Canada - English - Health Canada

samsung bioepis co., ltd - ranibizumab - solution - 10mg - ranibizumab 10mg